CST: 21/10/2016 06:11:58   

Part B Drug Payment Change: Understanding the Implications for Pharma, New Webinar Hosted by Xtalks

212 Days ago

TORONTO, ON --(Marketwired - March 22, 2016) - The session coming up on Monday, March 28, 2016, featuring industry experts from Xcenda, including Amanda Forys, MSPH, Director of Reimbursement Policy Insights and Jennifer Snow, MPH, Director of Health Policy, will focus on what's known about the proposed Medicare Part B drug payment model and what the implications are for pharmaceutical manufacturers. Additionally, the speakers will share strategies on how manufacturers will have to evolve to demonstrate product value.

Over the last six months, the Centers for Medicare & Medicaid Services (CMS) have hinted at changes in drug pricing, driven by their assertion that physician-drugs administered under Medicare Part B were potentially incentivizing providers to use more expensive medications. It wasn't until the proposed rule, known as the Part B Drug Payment Model, released on March 8th that the industry got a sense of just how big a change they were considering. Using a nationwide, mandatory payment model, CMS is upending the Part B payment system for drugs by proposing to test changes in the add-on payment as well as introducing value-based payment tools and strategies like indication-specific pricing and outcomes-based risk adjustment. Such a program represents the biggest proposed change in Medicare drug reimbursement in years.

During this webinar, participants will.

  • Gain insights on the proposed Medicare Part B drug payment model
  • Understand how the lessons from the commercial market's experience with value may influence the model
  • Learn what strategies pharmaceutical manufacturers should consider in demonstrating product value for the future

For more information or to register for this complimentary event, visit: Part B Drug Payment Change: Understanding the Implications for Pharma

About Xcenda

Xcenda, a part of AmerisourceBergen, is a strategic consulting firm with more than 20 years of experience applying real-world expertise in health economics and outcomes research, reimbursement, health policy, market research, and market access strategy. We support global pharmaceutical companies as well as emerging pre-commercialization phase firms with challenges such as developing an evidence package to optimize access in key global markets, predicting product performance, and identifying reimbursement strategies and programs to maximize patient access. From development through market maturity, Xcenda helps manufacturers identify, demonstrate, and deliver their brand's value proposition to key healthcare stakeholders.

For more information visit http://www.xcenda.com/.

About Xtalks

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com.

For information about hosting a webinar visit http://xtalks.com/sponsorship.ashx.

Image Available: http://www.marketwire.com/library/MwGo/2016/3/22/11G088614/Images/Xcenda_CMYK_(1)-301466508781.JPG

Dian Razak
Tel: +1 (416) 977-6555 ext 352
Email: drazak@xtalks.com